These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25584003)

  • 1. Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.
    Spitzer G; Socinski MA
    J Clin Oncol; 2015 Feb; 33(5):522-3. PubMed ID: 25584003
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to G. Spitzer and M.A. Socinski.
    Zer A; Leighl NB
    J Clin Oncol; 2015 Feb; 33(5):525-6. PubMed ID: 25584009
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to G. Spitzer and M.A. Socinski, F. Zhou et al, and B. Biswas.
    Kawaguchi T; Ando M; Kubo A
    J Clin Oncol; 2015 Feb; 33(5):526-7. PubMed ID: 25584006
    [No Abstract]   [Full Text] [Related]  

  • 4. Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
    Zer A; Leighl NB
    J Clin Oncol; 2014 Jun; 32(18):1874-81. PubMed ID: 24841982
    [No Abstract]   [Full Text] [Related]  

  • 5. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Singh N; Aggarwal AN
    Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
    [No Abstract]   [Full Text] [Related]  

  • 6. Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer in the era of personalized medicine.
    Biswas B
    J Clin Oncol; 2015 Feb; 33(5):524. PubMed ID: 25584001
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Zalcman G; Bergot E
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
    [No Abstract]   [Full Text] [Related]  

  • 8. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 9. Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
    Bunn PA
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5919-20. PubMed ID: 17062660
    [No Abstract]   [Full Text] [Related]  

  • 10. Second-line erlotinib for non-small-cell lung cancer.
    Lorusso V; Cinieri S
    Lancet Oncol; 2012 Apr; 13(4):e141-2; author reply e142. PubMed ID: 22469123
    [No Abstract]   [Full Text] [Related]  

  • 11. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
    Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
    Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TAILOR study: to agree or to disagree?
    Moro-Sibilot D; Perol D; Chabaud S; Cadranel J; Audigier Valette C; Perol M
    Lung Cancer; 2014 Jun; 84(3):315-6. PubMed ID: 24751106
    [No Abstract]   [Full Text] [Related]  

  • 13. Gefitinib or docetaxel in advanced non-small-cell lung cancer.
    Cullen M; Thatcher N
    Lancet; 2008 Nov; 372(9652):1785-6. PubMed ID: 19027472
    [No Abstract]   [Full Text] [Related]  

  • 14. Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
    Dafni U; Karlis D; Smit E; Peters S
    Lung Cancer; 2014 Jun; 84(3):314-5. PubMed ID: 24685307
    [No Abstract]   [Full Text] [Related]  

  • 15. Gefitinib versus docetaxel for previously treated NSCLC--letter.
    Tassinari D; Lazzari-Agli L; Tombesi P; Sartori S
    Clin Cancer Res; 2011 Jul; 17(13):4610; author reply 4611. PubMed ID: 21712456
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drug.
    Zhou F; Chen X; Zhou C
    J Clin Oncol; 2015 Feb; 33(5):523-4. PubMed ID: 25584007
    [No Abstract]   [Full Text] [Related]  

  • 17. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer: Squiring immunotherapy to CheckMate.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Aug; 12(8):436. PubMed ID: 26122186
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
    Cappuzzo F
    Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
    [No Abstract]   [Full Text] [Related]  

  • 20. Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
    Paz-Ares L
    Lancet Oncol; 2012 Mar; 13(3):225-7. PubMed ID: 22277836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.